RPL9 Antibody

What is RPL9 and what are its known functions in cellular biology?

RPL9 is a component of the 60S ribosomal subunit and belongs to the L6P family of ribosomal proteins. Beyond its canonical role in protein synthesis, RPL9 has been implicated in cancer progression through multiple mechanisms. Research shows that RPL9 expression is elevated in colorectal cancer (CRC) tissues compared to healthy colon tissue, suggesting its potential role in carcinogenesis . Additionally, RPL9 has been identified as an RNA-binding protein that can directly bind to specific miRNAs and be co-transported to receptor cells through exosomes, thereby exerting oncogenic effects .

Which RPL9 antibodies are most commonly used in cancer research applications?

Based on recent publications, researchers frequently use antibodies such as ab182556 from Abcam for western blotting applications in colorectal cancer research . For studies involving RNA immunoprecipitation and co-immunoprecipitation assays, the 202771-T44 antibody from Sino Biological has been successfully employed in hepatocellular carcinoma research . When selecting an RPL9 antibody, it is crucial to consider the specific application and experimental conditions.

How should RPL9 antibodies be validated before experimental use?

Proper validation of RPL9 antibodies should include:

• Western blotting to confirm target protein size and specificity

• Testing the antibody in RPL9 knockdown samples (using established siRNA sequences such as "gaTG GTA TCT ATG TCT CTG AA")

• Verifying cross-reactivity in multiple cell lines (e.g., Hep3B, SNU182, SNU387, Huh7, MHCC97H for liver cancer research)

• Including appropriate positive and negative controls in each experiment

What are the optimal conditions for western blotting with RPL9 antibodies?

For effective western blotting detection of RPL9:

• Prepare cell lysates using RIPA buffer containing protease and phosphatase inhibitor cocktail

• Quantify protein using a BCA Protein Assay Kit

• Separate approximately 50 μL of total protein using 10% SDS-PAGE

• Transfer to a PVDF membrane

• Block with 5% skim milk in Tris-buffered saline plus Tween 20

• Incubate with RPL9 primary antibody (e.g., ab182556 from Abcam)

• Use β-actin (e.g., sc-47778 from Santa Cruz Biotechnology) as a loading control

This protocol has been successfully used to detect RPL9 levels in colorectal cancer stem cells after siRNA transfection.

How can I optimize RNA immunoprecipitation (RIP) assays using RPL9 antibodies?

RIP assays for RPL9 should follow this optimized protocol:

• Prepare lysates from either serum exosomes (500 μl of patient serum) or cell lines (2×10^7 cells)

• Mix 50 μl of magnetic beads protein A/G suspension with RPL9 antibodies (5 μg per IP)

• Incubate for 30 minutes at room temperature

• Combine the lysate with the beads-antibody complex and incubate overnight at 4°C

• Extract, separate, and purify the immunoprecipitated RNA

• Transform total RNA into cDNA using miRNA first-strand cDNA synthesis kit

• Identify binding miRNAs by RT-qPCR

This method is particularly valuable for identifying miRNAs that interact with RPL9 in exosomes.

What considerations are important for co-immunoprecipitation experiments with RPL9 antibodies?

For effective co-immunoprecipitation of RPL9 and its binding partners:

• Lyse cells with IP lysis buffer containing protease and phosphatase inhibitors

• Use 0.5 mg of cell lysate diluted to 300 μl in 1X PBS

• Add 4 μg of anti-RPL9 antibody and appropriate IgG control

• Incubate at 4°C overnight

• Add 50 μl protein A/G magnetic beads and incubate at room temperature for 4 hours

• Wash beads with 1X PBS containing 0.5% Triton

• Treat with 2X loading buffer and heat at 95°C for 5 minutes

• To avoid interference from IgG heavy chain, use anti-heavy chain secondary antibodies

This approach has successfully identified interactions between RPL9 and exosomal proteins such as TSG101, VPS4A, Alix, CD63, and HSP90.

How does RPL9 contribute to cancer stem cell biology?

Recent research has established that RPL9 plays a critical role in maintaining cancer stem cell properties:

• RPL9 knockdown significantly suppresses the proliferative potential of CD133+ colorectal cancer stem cells

• This suppression is accompanied by reduction in CD133, ID-1, and p-IκBα levels

• Targeting RPL9 inhibits invasion, migration, and sphere-forming capacity of CD133+ cancer stem cells

• The mechanism appears to involve the ID-1 signaling axis, as decreased ID-1 expression was observed in all experimental CRC environments with RPL9 depletion

These findings suggest that RPL9 maintains stemness in colorectal cancer through ID-1-dependent mechanisms, making it a potential therapeutic target.

What is the relationship between RPL9 and exosome-mediated cancer progression?

RPL9 has been identified as an oncogenic factor in exosome-mediated cancer progression:

• RPL9 is significantly upregulated in serum exosomes of hepatocellular carcinoma (HCC) patients compared to benign liver disease patients

• Higher RPL9 content is observed in serum exosomes of patients with advanced HCC (TNM stage III/IV) compared to early-stage patients

• RPL9 can directly bind to specific miRNAs and be transported to receptor cells through exosomes

• Higher serum exosome RPL9 levels correlate with poor postoperative survival in HCC patients

This evidence suggests that RPL9 functions as an RNA-binding protein that facilitates exosome-mediated intercellular communication in cancer.

How do different RPL9 variants affect cellular function?

Studies have shown that different RPL9 variants can have distinct functional consequences:

• Variants in the 5′UTR of RPL9 (such as c.-2+1G>C) significantly impair erythroid cell proliferation and differentiation, promoting apoptosis through TP53 pathway activation

• These 5′UTR variants lead to reduced RPL9 protein levels and defects in 60S ribosomal subunit formation

• In contrast, missense variants (such as p.Leu20Pro) can affect pre-rRNA processing without significantly altering TP53 activation or erythroid development

• Despite causing similar pre-rRNA processing defects, different RPL9 variants can lead to markedly different clinical phenotypes

This differential impact of RPL9 variants highlights the complex relationship between ribosomal protein function and disease manifestation.

What are common issues when using RPL9 antibodies in western blotting and how can they be resolved?

Researchers may encounter several challenges when using RPL9 antibodies:

Always include positive controls (cell lines known to express RPL9) and negative controls (RPL9 knockdown samples) to validate results.

How should I interpret changes in RPL9 expression in relation to cancer progression?

When analyzing RPL9 expression data:

• Compare RPL9 levels between tumor and adjacent normal tissue (RPL9 is typically upregulated in colorectal and hepatocellular carcinomas)

• Correlate RPL9 expression with cancer stage (higher RPL9 levels often correspond with advanced disease)

• Assess the relationship between RPL9 expression and stemness markers (e.g., CD133 in colorectal cancer)

• Evaluate RPL9 content in serum exosomes as a potential biomarker for disease progression and prognosis

Increased RPL9 expression generally correlates with more aggressive disease characteristics and poorer outcomes.

What controls are essential when studying RPL9 in cancer stem cells?

When investigating RPL9 in cancer stem cells, include:

• Comparison between isolated stem cell populations (e.g., CD133+) and non-stem cell populations (CD133-) from the same parental cell line

• Control siRNA (non-targeting) alongside RPL9-specific siRNA

• Multiple stemness markers beyond CD133 (e.g., ID-1, sphere formation capacity)

• Functional assays (invasion, migration) to confirm phenotypic effects of RPL9 modulation

• Downstream signaling pathway components (p-IκBα) to validate mechanism

These controls ensure reliable interpretation of RPL9's specific role in cancer stemness.

How can RPL9 antibodies be used to investigate ribosome biogenesis defects?

RPL9 antibodies are valuable tools for studying ribosome assembly disorders:

• Western blotting to quantify RPL9 protein levels in cells with different RPL9 variants

• Immunofluorescence to visualize RPL9 localization in nucleoli and cytoplasm

• Polysome profiling combined with RPL9 immunodetection to assess incorporation into 60S subunits

• Co-immunoprecipitation to identify altered interactions with other ribosomal proteins or assembly factors

These approaches can help elucidate how RPL9 variants differentially affect ribosome biogenesis and related cellular processes.

What are emerging applications of RPL9 antibodies in therapeutic target validation?

RPL9 antibodies are increasingly important in validating this protein as a therapeutic target:

• Confirming efficient knockdown in siRNA or shRNA experiments targeting RPL9

• Evaluating RPL9 expression in patient-derived xenograft models

• Monitoring RPL9 levels in response to potential therapeutic compounds

• Assessing RPL9-dependent pathways (ID-1, stemness markers) during drug development

As RPL9 emerges as a potential therapeutic target for both primary colorectal cancer treatment and prevention of metastasis/recurrence, antibodies play a crucial role in validating intervention strategies.

How can RPL9 antibodies help identify novel binding partners and functional networks?

To discover new RPL9 interactions and functions:

• Employ immunoprecipitation followed by mass spectrometry to identify protein binding partners

• Use RNA immunoprecipitation and RNA-seq to characterize the RPL9-bound transcriptome

• Combine with CLIP-seq techniques to map precise RNA binding sites

• Apply proximity labeling approaches (BioID, APEX) with RPL9 antibody validation to identify transient interactions

These approaches have revealed unexpected roles for RPL9 beyond ribosome function, including its involvement in miRNA shuttling through exosomes.